申请人:Zeneca Limited
公开号:US05654299A1
公开(公告)日:1997-08-05
The present invention concerns the novel use of aryl substituted heterocycles of formula I, set out below, which antagonize the pharmacological actions of one of ent endogenous neuropeptide tachykinins an the neurokinin 2 (NK2) receptor making them useful whenever such antagonism is desired, such as in the treatment of asthma and related conditions. The invention also provides pharmaceutical compositions containing the aryl substituted heterocycles for use in such treatment. Certain novel aryl substituted heterocycles of formula I and novel intermediates for their manufacture are also provided. ##STR1##
本发明涉及下面列出的式I的芳基取代杂环化合物的新用途,这些化合物拮抗一种内源性神经肽激肽素和神经激肽2(NK2)受体的药理作用,使其在需要这种拮抗作用的情况下非常有用,例如在治疗哮喘和相关疾病时。该发明还提供了含有这些芳基取代杂环化合物的药物组合物,用于这种治疗。还提供了某些新型的式I的芳基取代杂环化合物以及用于它们制备的新型中间体。